J. Edmonson

发表

Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease.

T. Fleming, J. Edmonson, D. Decker, 1979, Cancer treatment reports.

Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962.

J. Edmonson, J. Edmonson, P. Carbone, 1965, Cancer research.

Estrogen replacement therapy: current recommendations.

P. Carpenter, J. Edmonson, G. Malkasian, 1988, Mayo Clinic proceedings.

Phase II Studies of Bleomycin, Cyclophosphamide, Doxorubicin and Cisplatin, and Bleomycin and Cisplatin in Advanced Cervical Carcinoma

J. Edmonson, G. Malkasian, J. A. Jefferies, 1988, American journal of clinical oncology.

Treatment of recurrent and metastatic carcinoma of the cervix: comparison of doxorubicin with a combination of vincristine and 5-fluorouracil.

J. Edmonson, D. Decker, G. Malkasian, 1981, Gynecologic oncology.

Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.

J. Edmonson, G. Malkasian, J. Laurie, 1989, Journal of the National Cancer Institute.

Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung.

S. Lagakos, G. Wampler, J. Edmonson, 1976, Cancer treatment reports.

Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.

J. Edmonson, D. Decker, G. Malkasian, 1978, Gynecologic oncology.

Cutaneous reactions to granulocyte-monocyte colony-stimulating factor.

J. Edmonson, D. Mehregan, A. Fransway, 1992, Archives of dermatology.

A clinical evaluation of a prolonged schedule of cytosine arabinoside (NSC63878).

J. Edmonson, B. Shnider, P. Burke, 1970, Cancer research.

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.

D. Alberts, W. Sauerbrei, M. Buyse, 1998, British Journal of Cancer.

Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma.

J. Edmonson, G. Malkasian, J. A. Jefferies, 1987, Gynecologic oncology.

Randomized Phase II studies of cisplatin and a combination of cyclophosphamide‐doxorubicin‐cisplatin (CAP) in patients with progestin‐refractory advanced endometrial carcinoma

J. Edmonson, J. Krook, J. Hilton, 1988 .

Granulocyte‐macrophage colony‐stimulating factor: Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin

L. Hartmann, J. Edmonson, J. A. Jefferies, 1992, Cancer.

Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas.

T. Fleming, J. Edmonson, G. Malkasian, 1985, Cancer treatment reports.

Medroxyprogesterone acetate for the treatment of metastatic and recurrent ovarian carcinoma.

J. Edmonson, D. Decker, G. Malkasian, 1977, Cancer treatment reports.

Evaluation of treatment and survival after positive second‐look laparotomy

J. Edmonson, G. Malkasian, J. A. Jefferies, 1989, Gynecologic oncology.

Mechlorethamine (NSC-762) plus CCNU (NSC-79037) in the treatment of inoperable squamous and large cell carcinoma of the lung.

S. Lagakos, J. Edmonson, J. Bennett, 1976, Cancer treatment reports.